Danaher (DHR)
(Delayed Data from NYSE)
$275.19 USD
+3.54 (1.30%)
Updated Jul 30, 2024 04:00 PM ET
After-Market: $273.89 -1.30 (-0.47%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$275.19 USD
+3.54 (1.30%)
Updated Jul 30, 2024 04:00 PM ET
After-Market: $273.89 -1.30 (-0.47%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Zacks News
Danaher Corporation is a global conglomerate that designs, manufactures and markets diverse lines of professional, industrial, commercial and consumer products.
Here's Why it is Worth Buying General Electric (GE) Stock Now
by Zacks Equity Research
General Electric (GE) is likely to gain from restructuring efforts, organic growth opportunities in some segments, reduction of debt levels and expansion in emerging markets.
Danaher (DHR) Names New Dental Company Envista Holdings
by Zacks Equity Research
Danaher (DHR) plans to create a separate dental company Envista, which will be listed on the New York Stock Exchange, and is likely to employ 12,000 people globally.
The Zacks Analyst Blog Highlights: Berkshire Hathaway, salesforce, Danaher, Halliburton and American Airlines
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Berkshire Hathaway, salesforce, Danaher, Halliburton and American Airlines
Here's Why it is Worth Holding on to Danaher (DHR) Stock Now
by Zacks Equity Research
Danaher (DHR) stands to gain from solid product portfolio, acquisitive nature and shareholder-friendly policy. High costs and debts as well as forex woes remain concerning.
Top Stock Reports for Berkshire Hathaway, salesforce & Danaher
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway (BRK.B), salesforce (CRM) and Danaher (DHR).
ITT vs. DHR: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ITT vs. DHR: Which Stock Is the Better Value Option?
CKHUY or DHR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CKHUY vs. DHR: Which Stock Is the Better Value Option?
Danaher (DHR) Up 3.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Danaher (DHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CKHUY vs. DHR: Which Stock Is the Better Value Option?
by Zacks Equity Research
CKHUY vs. DHR: Which Stock Is the Better Value Option?
General Electric (GE) Q1 Earnings Beat Estimates, Down Y/Y
by Zacks Equity Research
General Electric's (GE) first-quarter 2019 results decline year over year due to weak sales performance and fall in margins. However, results surpass estimates.
The Zacks Analyst Blog Highlights: Roche, Danaher, BlackRock, Kinder Morgan and Allstate
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Roche, Danaher, BlackRock, Kinder Morgan and Allstate
Top Research Reports for Roche, Danaher & BlackRock
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Roche (RHHBY), Danaher (DHR) and BlackRock (BLK).
Honeywell (HON) Q1 Earnings & Revenues Outpace Estimates
by Zacks Equity Research
Solid long-cycle businesses in U.S. defense, commercial aerospace, and warehouse and process automation drive Honeywell's (HON) Q1.
Danaher (DHR) Q1 Earnings Top, View Down on Buyout Impact
by Zacks Equity Research
Danaher's (DHR) first-quarter 2019 results gain from sales growth and DBS initiatives. It lowers projection for 2019 to include the dilutive impact of the BioPharma buyout.
Danaher (DHR) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Danaher's (DHR) first-quarter 2019 results to gain from solid product portfolio, innovative capabilities, Danaher Business System and acquired assets. Forex woes, tariffs and high costs drag.
Danaher (DHR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Analyst Reports for Mastercard, Honeywell & Thermo Fisher
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), Honeywell (HON) and Thermo Fisher (TMO).
UTX or DHR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
UTX vs. DHR: Which Stock Is the Better Value Option?
UTX vs. DHR: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
UTX vs. DHR: Which Stock Is the Better Value Option?
Danaher to Gain From Solid Demand in Key Markets Amid Risks
by Zacks Equity Research
Effective implementation of Danaher Business System and solid demand for innovative products are likely to boost Danaher's (DHR) revenues.
Danaher's Stock Offering Proceeds to Fund BioPharma Buyout
by Zacks Equity Research
Danaher (DHR) successfully completes the offering of common and preferred shares. It intends on using the funds raised to pay for the pending acquisition of General Electric's BioPharma business.
GE Intends to Lower Debt Burden, Boost Dividend Payments
by Zacks Equity Research
General Electric (GE) seeks to become more competent on the back of its initiatives to improve financial position and strengthen core businesses.
Danaher to Buy BioPharma, Offers Common & Preferred Shares
by Zacks Equity Research
Danaher (DHR) to gain from the buyout of the BioPharma business. This is likely to strengthen its biologics workflow solutions business. The company offers common and preferred shares.
General Electric (GE) to Divest BioPharma, Closes Wabtec Deal
by Zacks Equity Research
General Electric (GE) to gain from divestiture of the BioPharma business by using the proceeds to lower debt burden and focus on more important portfolios. It completes GE Transportation divestment.
Company News For Feb 26, 2019
by Zacks Equity Research
Companies In The News Are: DHR,GE,ONCE,CMTA,CRI